SynthesisCPT: pharmacometrics & systems pharmacology2026
Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis.
Synthesis in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis.CPT: pharmacometrics & systems pharmacology · 2026Pooled it
- Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- A Novel Unadjuvanted Subunit Respiratory Syncytial Virus Prefusion F Vaccine Induces Potent and Differentiated Functional Immune Responses Compared to AS01-Adjuvanted Arexvy in Older Adults.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objectives of this study were to quantify the relationship between vaccine-induced immunogenicity responses and the protection against respiratory syncytial virus (RSV) infection-related clinical outcomes, and to evaluate immunogenicity as a surrogate marker for vaccine efficacy (VE) to accelerate RSV vaccine development. Serum neutralizing activity (SNA) and cell-mediated immunity (CMI) may serve as surrogate markers for the protection against RSV infection and are evaluated as immunogenicity endpoints in clinical trials of RSV vaccine candidates. Two meta-analytical approaches were applied to data from seven randomized placebo-controlled clinical trials that investigated RSV vaccines in older adults. The primary analysis examined the relationship between SNA and VE across three different clinical severity levels: (1) acute respiratory infection, (2) RSV lower respiratory tract disease (LRTD) with ≥ 2 clinical symptoms, and (3) RSV LRTD with ≥ 3 clinical symptoms (LRTD 3+). Furthermore, the additional contribution of CMI to VE, after accounting for the effect of SNA, was explored in a secondary analysis. The results demonstrated a positive correlation between SNA and VE across three clinical severity levels. Higher CMI was associated with higher VE specifically for RSV LRTD 3+, the most severe clinical level, suggesting that CMI may be correlated with additional clinical benefits in mitigating the severity of RSV infection. These findings provided preliminary evidence for immune correlates of protection against RSV infection and may aid in accelerating the development of new RSV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.